Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02969174|
Expanded Access Status : Approved for marketing
First Posted : November 21, 2016
Last Update Posted : November 21, 2016
To establish a genotyping and extraction technology of non invasive prenatal diagnosis for fetal blood group genotype from cell-free fetal DNA in peripheral blood of pregnant women.
To achieve prenatal accurate identification of fetal blood group genotypes，and provide credible theoretical evidence for the prenatal diagnosis and treatment of hemolytic disease of newborn (HDN).
|Condition or disease||Intervention/treatment|
|HDFN||Other: zimin Lu,Guo Sa|
|Study Type :||Expanded Access|
|Official Title:||Clinical Professor of Shanghai Tongji Hospital|
- Other: zimin Lu,Guo Sa